AR086186A1 - ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND - Google Patents

ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND

Info

Publication number
AR086186A1
AR086186A1 ARP120101349A AR086186A1 AR 086186 A1 AR086186 A1 AR 086186A1 AR P120101349 A ARP120101349 A AR P120101349A AR 086186 A1 AR086186 A1 AR 086186A1
Authority
AR
Argentina
Prior art keywords
compound
subgenotypes
population
kit
hcv infection
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Federico Mensa
Gerhard Nehmiz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Priority to ARP120101349 priority Critical patent/AR086186A1/en
Publication of AR086186A1 publication Critical patent/AR086186A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de infección viral por hepatitis C (HCV) o alivio de uno o varios de sus síntomas en un paciente que comprende la etapa de administración al paciente de una combinación terapéutica, caracterizado porque comprende: (a) un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables; en donde B es un resto de fórmula (3); L0 es MeO-; L1 es Br; y R2 es un resto de fórmula (4); (b) un compuesto de la fórmula (2) o una de sus sales farmacéuticamente aceptables; y opcionalmente (c) ribavirina; y en donde el paciente tiene un genotipo CC o no CC de SNP rs12979860 o un genotipo TT o no TT de SNP rs 8099917 ubicado cerca del gen IL28B.Claim 1: A method of treating hepatitis C viral infection (HCV) or alleviating one or more of its symptoms in a patient comprising the stage of administration to the patient of a therapeutic combination, characterized in that it comprises: (a) a compound of the formula (1) or a pharmaceutically acceptable salt thereof; where B is a remainder of formula (3); L0 is MeO-; L1 is Br; and R2 is a residue of formula (4); (b) a compound of the formula (2) or a pharmaceutically acceptable salt thereof; and optionally (c) ribavirin; and where the patient has a CC or non-CC genotype of SNP rs12979860 or a TT or non-TT genotype of SNP rs 8099917 located near the IL28B gene.

ARP120101349 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND AR086186A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP120101349 AR086186A1 (en) 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP120101349 AR086186A1 (en) 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND

Publications (1)

Publication Number Publication Date
AR086186A1 true AR086186A1 (en) 2013-11-27

Family

ID=50185256

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101349 AR086186A1 (en) 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND

Country Status (1)

Country Link
AR (1) AR086186A1 (en)

Similar Documents

Publication Publication Date Title
CO2019000069A2 (en) Antiviral agents against hepatitis b
CL2011000571A1 (en) Use of a combination of: a) a compound of formula (1) or a pharmaceutically acceptable salt thereof, b) interferon alfa and c) ribavirin to prepare a medicament useful for the treatment of a viral infection of hepatitis c (hcv) or to relieve one or more symptoms of it.
EA201401281A1 (en) D-AMINO ACID CHEMICAL COMPOUNDS FOR THE TREATMENT OF LIVER DISEASES
EA201170915A1 (en) PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE FOR THE TREATMENT OF VIRAL INFECTIONS
CR20140086A (en) COMBINATION TREATMENTS FOR HEPATITIS C
EA201991174A1 (en) COMBINATION OF TWO ANTIVIRAL DRUGS FOR TREATMENT OF HEPATITIS C
CO6761335A2 (en) Hepatitis C virus inhibitors
EA201290993A1 (en) NUCLEOSIDOPHOSPHORAMIDATES
DOP2014000049A (en) METHODS FOR HCV TREATMENT THAT INCLUDE AT LEAST TWO DIRECT ACTION ANTIVIRAL AGENTS (DAAAS) AND RIBAVIRINE BUT NOT INTERFERONED
EA201290131A1 (en) Derivatives of Purine or Deazapurine for Use in the Treatment of Viral Infections and Other Diseases
UY30392A1 (en) HEPATITIS C PROTEASE INHIBITING MACROCICLIC OXIMYL COMPOUNDS
UY32793A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS AND ITS USES
ECSP13012551A (en) COMBINATION THERAPY TO TREAT HCV INFECTION.
EA201391685A1 (en) HEPATITIS C VIRUS INHIBITORS
RU2015114543A (en) HEPATITIS TREATMENT METHODS
GT201300172A (en) INHIBITORS OF SERINE PROTEASE OF HEPATITIS C BASED ON FENANTRIDINE MACROCICILICS
BR112014013972A8 (en) hcv inhibitors nssa
DOP2014000030A (en) PROCEDURES FOR THE MANUFACTURE OF USEFUL DRUGS FOR THE TREATMENT OF VIRAL INFECTIONS
CO7131387A2 (en) Compositions and methods of oligonucleotide chelate complex-polypeptides
EA201170605A1 (en) CYCLONE DECADEPSYPE COMPOUNDS AND APPLICATION OF THE SPECIFIED COMPOUNDS AS A MEDICINE
EA201170484A1 (en) THERAPEUTIC MODE OF HEPATITIS TREATMENT, INCLUDING PEG-INTERFERON, RIBAVIRIN AND VX-950
BR112013024880A2 (en) hcv treatment selection
RU2015114566A (en) HEPATITIS TREATMENT METHODS
AR086186A1 (en) ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND
AR086185A1 (en) ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure